Number of voting rights and shares as of May 31, 2017

27 Jun 2017 17:55 CEST

Total number of voting rights and shares

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).

*Including 5.210.000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on November 20^th 2014,the second planned tranche was put in place on November 30, 2016, representing an amount raised of  3. 937.400€. A shareholder holding 1.0% of the Company share capital (April 30^th, 2017) would be reduced to approximately 0, 88% of the capital on non-diluted basis. A total of 8, 510, 000 new shares have been issued since the beginning of the second tranche”

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

For more information on Neovacs, visit www.neovacs.fr

NEOVACS – Investor Relations

Charlène Masson

+33 (0)1 53 10 93 00

cmasson@neovacs.com

Investor Relations / Financial Communications – Life Science Advisors

Chris Maggos

chris@lifesciadvisors.com

Connect_neovacs_regulated-information-reglementee31052017.pdf